SARS-CoV-2 nucleocapsid protein N-terminal domain (N-NTD)

The **SARS-CoV-2 nucleocapsid protein N-terminal domain (N-NTD)** is a globular domain within the viral nucleocapsid (N) protein, primarily responsible for binding viral RNA. It plays a crucial role in **genome packaging**, forming part of the ribonucleoprotein complex during virion assembly and contributing to viral replication and transcription[1][2][3][5][8]. The N-NTD exhibits a conserved **RNA-binding pocket** and unique electrostatic surface properties that facilitate interaction with the viral RNA genome through electrostatic interactions and specific residue contacts[2][3][4][5][8]. Its critical function and druggability make it an attractive target for the development of antiviral agents designed to disrupt the formation of infectious SARS-CoV-2 particles[5][8]. The N protein, including N-NTD, is also a **diagnostic marker** in rapid antigen tests used for COVID-19 detection[5]. Currently, no drugs are approved that directly target the N-NTD, but multiple structural studies have identified binding pockets suitable for small-molecule inhibitor development[2][5][8].

Other names

N-terminal RNA-binding domain of SARS-CoV-2 nucleocapsid proteinN-NTDnucleocapsid N-terminal domainNTD

Inhibition of RNA-binding activity, preventing viral genome encapsidation and assembly[2][5]. Disruption of N protein oligomerization, affecting viral replication[5].